L’immunothérapie, une révolution en oncologie

Dubois, Manon; Ardin, Camille; André, Fanny; Scherpereel, Arnaud; Mortier, Laurent

doi:10.1051/medsci/2019225

Cited by 9 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hao et al ’s meta-analysis of studies of immunotherapy in advanced melanoma reported that the risk ratio for an objective response (relative to chemotherapy) was 3.43 [5]. ICIs act by suppressing immune system inhibition and restoring anti-tumour activity [6]. The mechanism of action depends on the protein target: anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) agents inhibit the interaction between antigen-presenting cells and T lymphocytes, whereas anti-programmed cell death-1 (PD-1) agents act on the downstream interaction between T lymphocytes and tumor cells.…”

Section: Introductionmentioning

confidence: 99%

Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma

Leroy,

Desmedt,

Deramoudt

et al. 2024

Melanoma Research

Self Cite

View full text Add to dashboard Cite

Nivolumab was first authorized at a weight-based dose (WBD) of 3 mg/kg every two weeks (Q2W). Since 2017, a fixed dose (FD) regimen [first 240 mg Q2W and then 480 mg per month (Q4W)] was allowed. The objective of the study was to compare a WBD regimen and an FD regimen with regard to effectiveness and safety. We conducted a single-center, retrospective, real-life study of consecutive adult patients who had received a WBD of nivolumab or an FD of 480 mg Q4W. The primary endpoint was the occurrence of grade ≥3 immune-related adverse events (irAEs). The secondary endpoints were overall survival and cost of the treatment. In all, 342 patients were included: 71 in the WBD cohort and 271 in the FD cohort. 201 patients (59.6%) experienced an irAE, and 24 of these events were graded as ≥3. At 12 months, there was no significant difference in irAE occurrence between the two cohorts [hazard ratio (95% confidence interval): 0.54 (0.21–1.36), P = 0.19]. The 12-month overall survival rate was significantly lower in the WBD cohort (P < 0.001). Switching from a fortnightly weight dose to a fixed monthly dose halves the cost of hospitalization. Our results did not show a significant difference between WBD and FD cohort in the occurrence of severe irAEs. However Overall survival appeared to be significantly higher in FD group. Some clinical trials are investigating a hybrid dosing regimen in which a WBD is capped by an FD. The present results need to be confirmed in prospective studies.

show abstract

Section: Introductionmentioning

confidence: 99%